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Surfactant proteins SP-A and SP-D are hydrophilic, collagen-containing calcium-dependent
lectins, which appear to have a range of innate immune functions at pulmonary as well
as extrapulmonary sites. These proteins bind to target ligands on pathogens, allergens,
and apoptotic cells, via C-terminal homotrimeric carbohydrate recognition domains, while
the collagen region brings about the effector functions via its interaction with cell surface
receptors. SP-A and SP-D deal with various pathogens, using a range of innate immune
mechanisms such as agglutination/aggregation, enhancement of phagocytosis, and killing
mechanisms by phagocytic cells and direct growth inhibition. SP-A and SP-D have also
been shown to be involved in the control of pulmonary inﬂammation including allergy and
asthma. Emerging evidence suggest that SP-A and SP-D are capable of linking innate immu-
nity with adaptive immunity that includes modulation of dendritic cell function and helperT
cell polarization.This review enumerates immunological properties of SP-A and SP-D inside
and outside lungs and discusses their importance in human health and disease.
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INTRODUCTION
Surfactant proteins, SP-A and SP-D, are collagen-containing C-
type (calcium-dependent) lectins called collectins, which were
originally identiﬁed as surfactant-associated proteins involved in
pulmonary surfactant homeostasis (Weaver and Whitsett, 1991).
Subsequent studies involving structural and functional character-
ization of these proteins have suggested that SP-A and SP-D are
potent innate immune molecules in the lungs that are involved
in viral neutralization, clearance of bacteria, fungi, apoptotic and
necrotic cells, down regulation of allergic reaction and resolu-
tion of inﬂammation (Kishore et al., 2001, 2006; Wright, 2005).
Their primary structures include an N-terminal, triple-helical col-
lagen region, and a C-terminal homotrimeric C-type lectin or
carbohydrate recognition domain (CRD). The trimeric CRDs can
recognize carbohydrate or charge patterns on microbes, allergens,
and dying cells acting as a soluble pattern recognition receptors
(PRRs) while the collagen region can interact with receptor mol-
ecules present on a variety of immune cells in order to initiate
clearance mechanisms (Kishore et al., 2006).
SP-A and SP-D are large hydrophilic proteins, as opposed to
SP-B and SP-C, the other two hydrophobic surfactant proteins
found in the lungs. Their primary structure is organized into a
Abbreviations: ALI, acute lung injury; AM, alveolar macrophages; ARDS, acute res-
piratory distress syndrome; BAL, bronchoalveolar lavage; BALF, bronchoalveolar
lavage ﬂuid; COPD, chronic obstructive pulmonary disease; CRD, carbohydrate
recognition domain; DC, dendritic cells; IFN, interferon; IL, interleukin; LAM,
lipoarabinomannan; LPS, lipopolysaccharides; MMP, matrix metalloproteinases;
NO, nitric oxide; PAP, pulmonary alveolar proteinosis; PBMCs, peripheral blood
mononuclear cell; PG, prostaglandin; RA, rheumatoid arthritis; RSV, respiratory
syncytial virus; SP-A, surfactant protein A; SP-D, surfactant protein D; SR-A,
scavenger receptor A; TLR, toll-like receptor; TNF, tumor necrosis factor.
cysteine-containing N-terminal region, a triple-helical collagen
region composedof repeatingGly-X-Y triplets, anα-helical coiled-
coil neck region, and a C-terminus comprising a C-type lectin
or CRD region (reviewed in Kishore et al., 2006). SP-A and SP-
D are large oligomeric structures, each assembled from multiple
copies of either one or two polypeptide chains. SP-A has a hexam-
eric structure in which six structural subunits associate to form a
molecule of 630 kDa made up of 18 chains. SP-D is composed
of oligomers of a 130 kDa subunit comprising three identical
polypeptide chains of 43 kDa. Human SP-D is assembled into a
520 kDa tetrameric structure with four of the homotrimeric sub-
units linked via their N-terminal regions, but multimers, trimers,
dimers and monomers are also possible (Holmskov et al., 2003;
Kishore et al., 2006; Figures 1A,B).
SP-A and SP-D can bind various self and non-self ligands,
mostly via CRDs on the target surface in a carbohydrate and
calcium-dependent manner, while the collagen region can recruit
and activate the immune cells for the clearance of pathogens
and apoptotic/necrotic cells (Kishore et al., 2006) (Figure 2). In
addition to anti-microbial activities, SP-A and SP-D also play an
important role in the control of inﬂammation triggered by self,
non-self and altered self cells and molecules. Thus, they have a
pivotal role in the clearance of apoptotic and necrotic cells, damp-
ening of allergic reactions,maintenance of pregnancy (by virtue of
their presence in the amniotic ﬂuid), andmodulating dendritic cell
(DC) and T cell properties (Figure 2). The major immune-related
functions of SP-A and SP-D are being reviewed here.
ANTI-MICROBIAL PROPERTIES OF SP-A AND SP-D
SP-A and SP-D play a central role in the protection of the lungs
against respiratory infection. SP-A and SP-D are able to bind to a
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FIGURE 1 | Illustration of a molecule of (A) SP-A and (B) SP-D
depicting different regions.The molecules are ﬁrst shown as monomers
and trimers. They are divided into four subunits, the N-terminal
non-collagenous domain, collagenous region, helical neck, and C-terminal
carbohydrate recognition domain. Each sub-unit has different ligand
binding afﬁnities.
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FIGURE 2 | Multiple functions of (A) SP-D and (B) SP-A in human health and disease.
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variety of microbes (viruses, bacteria, yeast, and fungi), thus act-
ing as opsonins and having direct and indirect biological effects
(Crouch, 2000; Lawson and Reid, 2000; Crouch and Wright, 2001;
Shepherd, 2002; Tables 1 and 2). There is one report of SP-D
binding to the parasite Schistosoma mansoni (van de Wetering et
al., 2004b). SP-A and SP-D bind and/or agglutinate a wide range
of microbes that enhance their attachment to phagocytic cells and
can lead to killing and enhanced clearance. SP-A and SP-D deal
with various pathogens via a number of innate immune mecha-
nisms that include agglutination/aggregation, enhanced phagocy-
tosis, and superoxidative burst by phagocytes, chemotaxis, growth
inhibition, and modulation of toll-like receptor (TLR) functions
(Kishore et al., 2006).
INTERACTION WITH BACTERIA
One of the ﬁrst studies showing that surfactant proteins may
be involved in pulmonary immunity against infection was con-
ducted 40 years ago and involved isolating total surfactant by
centrifugation and showed enhanced killing, but not phagocy-
tosis of Staphylococcus aureus by alveolar macrophages (AMs),
in vitro (LaForce et al., 1973). Subsequently, SP-A was shown to
enhance uptake of sensitized erythrocytes through Fc and comple-
ment receptor 1 (CR1) present on AMs (Tenner et al., 1989; van
Iwaarden et al., 1992).
SP-A and SP-D can bind to Gram-negative and Gram-positive
bacteria. Lipopolysaccharide (LPS) is an established ligand for
surfactant proteins and a major component of the cell wall of
Gram-negative bacteria. There are essentially two types of LPS.
Firstly, smooth LPS which is comprised of the O-speciﬁc anti-
gen, complete core oligosaccharides and the endotoxin-principal
region, lipid A. Secondly, rough LPS serotypes which lacks the
O-speciﬁc antigen, but has the lipid A region and increasingly
shorter core oligosaccharides in some bacterial mutants (Silhavy
et al., 2010).
SP-D was ﬁrst shown to bind to rough LPS via CRDs and agglu-
tinate Escherichia coli (Kuan et al., 1992). SP-A and SP-D can also
bind to rough serotypes of LPS, via contrasting mechanisms. SP-A
binds to the lipidA region of LPS (van Iwaarden et al., 1994; Kalina
et al., 1995). SP-D has been shown to bind via its trimeric CRDs
only rough LPS derived from a select species of Gram-negative
bacteria such as Klebsiella pneumoniae and Pseudomonas aerugi-
nosa (Lim et al., 1994; Kishore et al., 1996). SP-D binds strongly
to LPS from E. coli and Salmonella, but not to lipid A, LPS from
oligosaccharide deﬁcient strains or smooth LPS, suggesting that
core terminal sugar residues (e.g., heptose and glucose) may be
important in binding SP-D to LPS (Kuan et al., 1992). As with SP-
D, SP-A only seems to bind rough LPS (van Iwaarden et al., 1994),
often mediating subsequent phagocytosis and killing of the bac-
terium (Pikaar et al., 1995). SP-A binds also to lipid A and rough
serotypes of LPS lacking O-speciﬁc antigen, but not to smooth
LPS. SP-A has also been demonstrated to interact with the capsular
polysaccharides of Klebsiella species (Kabha et al., 1997).
SP-A and SP-D can directly inhibit the growth of Gram-
negative bacteria by increasing membrane permeability (Wu et al.,
2003). SP-A inhibits growth of P. aeruginosa by increasing mem-
brane permeability (van Iwaarden et al., 1994). However, a recent
study has shown that through quorum-sensing, P. aeruginosa is
able to resist SP-A activities, via a ﬂagellum-mediated mechanism
producing exoproteases that degrade SP-A (Kuang et al., 2011).
SP-A is not able to interact with peptidoglycan isolated from
Gram-positive bacteria (Murakami et al., 2002) or zymosan iso-
lated from yeast (Sato et al., 2003). In contrast,H. inﬂuenza typeA,
the major outer membrane protein, is a ligand for SP-A (McNeely
and Coonrod, 1994) whilst in Klebsiella, SP-A interacts with a cap-
sular polysaccharide (Kabha et al., 1997). However, SP-D interacts
with Gram-positive bacteria via binding to the cell wall com-
ponents lipoteichoic acid and peptidoglycan via CRDs (van de
Wetering et al., 2001). SP-D is also able to bind lipoarabinoman-
nan (LAM) from M. tuberculosis and M. avium (Ferguson et al.,
1999; Kudo et al., 2004) and to cell surface lipids on Mycoplasma
pneumoniae (Chiba et al., 2002). SP-A has been shown to bind
M. pneumonia via disaturated phosphatidylglycerol and is able
to attenuate its growth (Piboonpocanun et al., 2005). SP-A can
aggregate and opsonize H. inﬂuenza type A, but not type B, via the
P2 outer membrane protein (McNeely and Coonrod, 1994). SP-A
interacts with the M. tuberculosis cell surface Apa glycoprotein,
which is a potential adhesion molecule, and may facilitate uptake
of the pathogen by host cells (Ragas et al., 2007).
To date, a number of in vitro studies have shown that SP-
A and SP-D increase receptor-mediated uptake, independent of
serum, of a variety of microbes including bacteria (Lawson and
Reid, 2000). SP-A increases C1q-mediated uptake of S. aureus
(Greertsma et al., 1994). For Mycobacteria, SP-A increases man-
nose receptor-mediated uptake (Gaynor et al., 1995; Kudo et al.,
2004), and for Streptococcus pneumoniae, SP-A increases scavenger
receptor A (SR-A)-mediated uptake of the bacterium (Kuronuma
et al., 2004). Curiously, SP-D has been found to reduce uptake of
M. tuberculosis (Ferguson et al., 1999), but enhances phagocyto-
sis of Mycobacterium avium (Kudo et al., 2004). These opposing
effects of SP-A and SP-D on the uptake of M. tuberculosis sug-
gest different roles for SP-A and SP-D in the clearance of bacterial
infection. Thus, interaction of SP-A and SP-D with the pathogen
can either enhance or suppress their interactions with phagocytes.
SP-D reduces the uptake of M. tuberculosis by macrophages by
interacting directly with the bacterium (Ferguson et al., 1999) and
this effect does not involve bacterial agglutination (Ferguson et al.,
2002). In addition to enhancing phagocytosis via opsonization,
SP-A and SP-D can also directly stimulate phagocytosis, by the
upregulation of cell surface phagocytic receptors in macrophages,
without the need for microbial binding. This has been shown for
the mannose receptor on monocyte-derived macrophages, where
both SP-A and SP-D have been shown to up-regulate its activity
(Beharka et al., 2002; Kudo et al., 2004). Furthermore, in SP-A
gene-deﬁcient (SP-A-/-) mice, expression of mannose receptor is
decreased, suggesting that SP-A plays a central role in modulating
the activity of this receptor (Beharka et al., 2002). It has also been
found that SP-A enhances the phagocytosis of S. pneumoniae by
AMs, via signiﬁcant upregulation in the expression of cell surface
scavenger receptor A (SR-A; Kuronuma et al., 2004). The mech-
anisms (e.g., signaling pathways) by which collectin phagocytic
receptors actually trigger phagocytosis are not well understood. A
receptor for SP-A has been identiﬁed called SPR-210, which is a
210 kDa cell surface protein from a macrophage like cell line U973
(Chroneos et al., 1996) and is also found on type II Pneumocytes
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and AMs. Antibodies generated against SPR-210, inhibited the
enhancement by SP-A on the phagocytosis of Mycobacterium bovis
BCG by macrophages (Weikert et al., 2000). Subsequently, another
receptor called gp-340 was also found that binds SP-A and SP-D
(Holmskov et al., 1997; Tino and Wright, 1999).
SP-A and SP-D also play important roles modulating reactive
oxygen and nitrogen intermediates in the phagocytes during the
killing of intracellular bacteria. A number of studies have shown
that SP-A modulates this process in Mycobacterium-infected cells.
For example, SP-A enhances macrophage killing of M. bovis BCG
(Bacillus Calmette-Guérin) by increasing the level of NO (Weik-
ert et al., 2000). However, in IFN-γ stimulated macrophages, SP-A
decreases nitric oxide levels in response to M. tuberculosis and M.
avium (Pasula et al., 1999; Hussain et al., 2003). NO production
induced by IFN-γ is TNF-α dependant and it is thought that SP-A
decreases NO levels, by inhibiting TNF-α production and activa-
tion of the transcription factor NF-κB (Hussain et al., 2003). SP-A
is also found to enhance the killing of Mycoplasma pulmonis, by
increasing the levels of NO (Hickman-Davis et al., 1998).
Bacterial cell wall components such as LPS and peptidogly-
can (pathogen-associated molecular patterns; PAMPs) are potent
stimulators of inﬂammation and can also interact with PRRs such
as CD14 or TLR, and activate downstream intracellular signal-
ing. SP-A and SP-D can bind to PRRs and directly inﬂuence
the inﬂammatory response. For example, SP-A binds to CD14
on AMs, preventing the binding of smooth LPS to CD14, and
reducing TNF-α production (Sano et al., 1999). These ﬁndings
are supported by studies showing that TNF-α, which is induced
by smooth LPS, is signiﬁcantly increased in SP-A−/− compared to
wild-type mice (Borron et al., 2000). Equally, SP-A has also been
shown to inhibit the peptidoglycan-induced secretion of TNF-αby
directly binding to TLR-2 (Murakami et al., 2002). Therefore, the
presence of SP-A signiﬁcantly reduces peptidoglycan-inducedpro-
inﬂammatory cytokine responses and NF-κB activation. However,
SP-A enhances the pro-inﬂammatory response induced by rough
LPS. It is interesting that rough LPS is a ligand for SP-A, whereas
peptidoglycan is not. SP-A is thought to interact with CD14 via
its neck region, but binds with rough LPS via the CRD domain,
possibly resulting in a trimolecular complex (Sano et al., 1999).
INTERACTION OF SP-A AND SP-D WITH VIRUSES
Direct interaction of SP-A and SP-D with a number of viruses
more often results in viral neutralization and enhanced phago-
cytosis. For example, both SP-A and SP-D inhibit hemagglutinin
binding activity of inﬂuenza A virus (IAV) (Malhotra et al., 1993;
Hartshorn et al., 1994; Benne et al., 1995), whilst SP-D also
decreases neuraminidase activity (Reading et al., 1997). Moreover,
SP-D exhibits strong anti- IAV activity via its CRD region bind-
ing to carbohydrates (mannosylated, N-linked) on neuraminidase
and hemagglutinin of the virus (Hartshorn et al., 1994, 2000).
It appears that some Pandemic H1N1 IAV strains are resistant
to the neutralization by SP-A because of differences in the N-
glycosylation of viral hemagglutinin (Job et al., 2010). SP-A can
also interact with herpes simplex virus type 1 (HSV-1) via its N-
linkedoligosaccharides that results in SP-A-mediatedphagocytosis
of HSV-1 byAMs (van Iwaarden et al., 1991, 1992). SP-A can inter-
act with respiratory syncytial virus (RSV) (Hickling et al., 1999;
Sano et al., 1999) and binds to the F2 subunit of the F protein of
RSV and neutralizes the infectivity of the virus (Ghildyal et al.,
1999; Sano et al., 2003). Additionally, SP-D binds to RSV attach-
ment protein G and inhibits RSV infection in vivo and in vitro
(Hickling et al., 1999). A recent study has shown that RSV-infected
cells (a bronchiolar epithelial cell line) have a reduction in SP-A
protein levels via amechanism that affects SP-AmRNA translation
efﬁciency (Bruce et al., 2009).
SP-A has been found to bind to Human Immunodeﬁciency
Virus (HIV) gp120 and this inhibits direct infection of CD4+
cells, but also enhances the transfer of infection to CD4+ T cells
mediated by DCs (Gaiha et al., 2008). SP-D binds to HIV envelope
protein gp120 and inhibits HIV replication (Meschi et al., 2005).
SP-D recognizes the SARS corona virus spike glycoprotein and
can activate macrophages (Leth-Larsen et al., 2007). SP-D has also
been found to bind bovine strains of the non-enveloped rotavirus
via the VP7 glycoprotein (Reading et al., 2004). There is also a
report showing that SP-A can enhance viral clearance and inhibit
inﬂammation after pulmonary adenoviral infection (Harrod et al.,
1999).
INTERACTION OF SP-A AND SP-D WITH PRIMARY AND
OPPORTUNISTIC FUNGAL PATHOGENS
SP-A and SP-D have been shown to bind to a variety of fungi,
mostly opportunistic fungal pathogens, resulting in direct inhi-
bition of growth and enhancement phagocytosis. However, the
downstream immune response elicited by surfactant proteins can
also contribute to fungal pathogenesis.
SP-A and SP-D inhibit the growth of Histoplasma capsula-
tum directly by increasing the permeability of the cell membrane
(McCormack et al., 2003). SP-D has also been found to aggluti-
nateC. neoformans andAspergillus fumigatus (Schelenz et al., 1995;
Madan et al., 1997a). SP-A and SP-D bind to A. fumigatus coni-
dia and enhance phagocytosis and killing by neutrophils and AMs
(Madan et al., 1997a). In a murine model of invasive pulmonary
aspergillosis (IPA), SP-D, but not SP-A, was found to protect
immunosuppressed mice from an otherwise fatal challenge with
A. fumigatus conidia (Madan et al., 2001). In a further study, ther-
apeutic protection by native full-length SP-D (and a recombinant
fragment of human SP-D containing homotrimeric neck andCRD
domains, designated rhSP-D) was associated with a reduction in
the growth of fungal hyphae in the murine lungs, and increased
levels of TNF-α and IFN-γ (Singh et al., 2009). SP-Dgene-deﬁcient
(SP-D−/−) mice are also more susceptible to IPA,while SP-A gene-
deﬁcient (SP-A−/−) mice acquire resistance to IPA (Madan et al.,
2010), suggesting that SP-A may facilitate pathogenesis byA. fumi-
gatus. A. fumigatus-challenged SP-A-/- mice showed less mortality
(40%) than the wild-type mice (100%) and increased mortality
(60%) following administration of SP-A with decreased TNF-α
and IFN-γ to IL-4 ratio than SP-A-/- IPA mice. The SP-D-/- IPA
mice (57.14%) showed similar mortality as wild-type mice (60%).
However, the SP-D-/- IPA mice (42.86% mortality on day 2) died
earlier than the WT-IPA mice (20% mortality on day 2), showed a
higher hyphal density and tissue injury in lungs. Treatment with
SP-D or rhSP-D fragment reduced the mortality to 50 and 33%,
respectively, consistent with higher IFN-γ to IL-4 ratios in treated
SP-D-/- mice, compared to untreated control group. The results
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showed that SP-D-/- mice are more susceptible to IPA while SP-A
gene-deﬁcient mice acquire resistance to IPA (Madan et al., 2010).
The fungal ligands recognized by SP-A include the 45and
55 kDa glycoproteins secreted by A. fumigatus (Madan et al.,
1997b). SP-A also binds to a 120 kDa surface glycoprotein of Pneu-
mocystis jirovecii (formally P. carinii) (Zimmerman et al., 1992)
via its CRD region (McCormack et al., 1997). SP-D, but not SP-A,
binds to Saccharomyces cerevisiae cells, and the ligand for SP-Dwas
determined to be the yeast glucan, β-(1> 6)-glucan (Allen et al.,
2001). SP-Abinds toboth encapsulated andacapsularCryptococcus
neoformans, but does not appear to enhance acapsular C. neofor-
mans phagocytosis (Walenkamp et al., 1999). In contrast, SP-D
increases phagocytosis of hypocapsular C. neoformans by murine
macrophages and enhances fungal survival (Geunes-Boyer et al.,
2009). In a study involving SP-A−/− and wild-type mice and an
intranasal C. neoformans infection model, it was found that dis-
ease progression was not inﬂuenced by SP-A (Giles et al., 2007).
Both encapsulated and acapsular Cryptococci can bind SP-D, but
SP-D showed the highest afﬁnity and aggregation for acapsular
C. neoformans (van de Wetering et al., 2004a). The ligands for
SP-D were identiﬁed as capsular components glucuronoxyloman-
nan (GXM) and mannoprotein 1 (MP1) (van de Wetering et al.,
2004a).
SP-D also binds to Candida albicans, resulting in agglutination,
growth inhibition, decreased hyphal outgrowth and inhibition of
phagocytosis by AMs (van Rozendaal et al., 2000). Recent data has
suggested that SP-D binds toBlastomyces dermatitidis via β-glucan
molecule (Lekkala et al., 2006).
Recently, the roles of SP-A and SP-D have also been examined
in Coccidioides infection. Both SP-A and SP-D bind to Coccidio-
dal antigens, but it has been shown that Coccidioides infection also
disrupts the expression of pulmonary SP-A and SP-D, potentially
aiding pathogenesis (Awasthi et al., 2004).
ROLE OF SP-A AND SP-D IN THE CONTROL OF LUNG
HYPERSENSITIVITY AND INFLAMMATION
SP-A was ﬁrst shown to bind to pollen grains of Populas nigra
italica (Lombardy poplar), Poa prantensis (Kentucky blue grass),
Secale cerale (cultivated rye), andAmbrosia elatior (short ragweed)
in a calcium and carbohydrate (mannose) dependant manner
(Malhotra et al., 1993). SP-A, SP-D, and rhSP-D bind to 3-week
culture ﬁltrate (3wcf) and two immunodominant glycoprotein
allergens, gp45 and gp55, of A. fumigatus in a calcium, dose-
dependent and sugar-speciﬁc manner (Madan et al., 1997b), as
well as allergens derived from Dermatophagoides pteronyssinus
(house dust mite) (Wang et al., 1996, 1998). SP-A, SP-D, and
rhSP-D can inhibit speciﬁc IgE binding to the allergens of A. fumi-
gatus and block allergen-induced histamine release by basophils
(Madan et al., 1997b). Consistent with binding of SP-A, SP-D,
and rhSP-D binding to mite allergens and competitive inhibi-
tion of IgE-allergen interaction, SP-D reduces the proliferation of
peripheral blood mononuclear cells (PBMC) isolated from mite-
sensitive asthmatic children (Wang et al., 1998). Dodecameric
form of SP-D has been shown to induce aggregation of pollen
derived starch granules (PSG) derived fromDactylis glomerata and
Phleum pratense and increase their binding and uptake by AMs.
Pre-treatment of these PSG with SP-D resulted in inhibiting the
release of β-hexosaminidase in PSG induced IgE dependent mast
cell degranulation (Erpenbeck et al., 2005).
In view of the ability of SP-A and SP-D to inhibit IgE-mediated
histamine release by basophils, a number of allergic murine mod-
els have been used to examine in vivo effects of SP-A and SP-D
following allergenic challenge. Intranasal administration of SP-
D and rhSP-D in a murine model of pulmonary hypersensitivity
induced byA. fumigatus allergens and antigens suppressed speciﬁc
IgG and IgE levels in serum, reduced peripheral and pulmonary
eosinophilia, and caused helper T cell (Th) polarization fromaller-
gic Th2 to a protective Th1 phenotype (i.e., lowering the levels
of IL-4 and IL-5 and elevating IFN-γ level in the spleen super-
natant; Madan et al., 2001). The rhSP-D, when given intranasal
to Derp mice (a murine model of lung allergy induced by house
dust mite allergens) decreased Derp speciﬁc IgE levels, periph-
eral blood eosinophilia and pulmonary inﬁltration, in addition to
causing Th1 polarization (Singh et al., 2003).
The susceptibility of SP-A−/− or SP-D−/− mice to the A. fumi-
gatus allergen challenge, as compared with the wild-type mice,
has also been examined (Madan et al., 2005). Both SP-A−/− and
SP-D−/− mice show intrinsic hypereosinophilia and several-fold
increase in levels of IL-5 and IL-13, and lower IFN-γ to IL-4
ratio in the lungs, suggesting a Th2 bias of immune response.
This Th2 polarization was reversible by treating SP-A−/− or SP-
D−/− mice with exogenous intranasal SP-A or SP-D delivery,
respectively. SP-D−/− mice were found more susceptible than
wild-type mice to pulmonary hypersensitivity induced byA. fumi-
gatus allergens whilst SP-A−/− mice were found to be nearly
resistant to sensitization. Intranasal treatment with SP-D or rhSP-
D rescued the sensitized SP-D−/− mice, while SP-A-treated and
sensitized.
SP-A−/− mice showed several-fold elevated levels of IL-13 and
IL-5, resulting in increased pulmonary eosinophilia and dam-
aged lung tissue. These data validated important roles for SP-A
and SP-D in offering resistance to pulmonary allergenic challenge
(Erpenbeck et al., 2006).
In an interesting study, Haczku et al. (2006) have shown that
mice sensitized and challenged with either A. fumigatus have
increased SP-D levels in their lung that gets exaggerated further
in response to IL-4 or IL-13 treatment. STAT-6-deﬁcient mice as
well as in IL-4/IL-13 double knockout mice do not appear to have
upregulation of SP-D expression following A. fumigatus allergen
challenge. It is likely that SP-D protein levels, which is dependent
on IL-4 and IL-13, interferes with T cell sensitization, thus protect-
ing lungs from airway inﬂammation. Consistent with these in vivo
studies, when cultured alveolar type II cells are exposed to IL-13
or IFN-γ, the expression of surfactant proteins are altered in vitro
(Ito and Mason, 2010). IL-13 decreases SP-D in levels, whereas
IFN-γ has the opposite effect. Thus, over-expression of IL-13 can
lead to SP-D deﬁciency in the lungs.
SP-A and SP-D have been shown to modulate DCs and
eosinophils. The SP-D mediated binding and uptake of E. coli by
bonemarrow derivedmouseDCs has been shown to increase anti-
gen presentation of E. coli expressed proteins to a T cell hybridoma
(Brinker et al., 2001). Curiously, pre-treatment of immature DCs
with SP-A (and C1q) has been shown to inhibit LPS-mediated sur-
face expression of maturation markers: MHC class II and CD86.
Frontiers in Immunology | Molecular Innate Immunity June 2012 | Volume 3 | Article 131 | 8
Nayak et al. SP-A and SP-D in immunity
Stimulation of immature DCs by SP-A also inhibits the allostim-
ulation of T cells, enhances dextran endocytosis, and alters DCs
chemotaxis toward RANTES (Brinker et al., 2003).
In view of therapeutic effects of rhSP-D in murine models of
lung allergy (Madan et al., 2001; Singh et al., 2003) and hypere-
osinophilic SP-D gene-deﬁcient mice (Madan et al., 2005), direct
interaction of rhSP-D with human eosinophils derived from aller-
gic patients and healthy donors and its consequences have been
examined (Mahajan et al., 2008). The rhSP-D shows a sugar-
and calcium-dependent binding to human eosinophils, suggest-
ing binding via CRD region. Compared to eosinophils derived
from non-allergic healthy donors, eosinophils derived from aller-
gic patients show a signiﬁcant increase in apoptosis, oxidative
burst and CD69 expression in the presence of rhSP-D. However,
eosinophils from healthy donors, when primed with IL-5, show an
increase in apoptosis on incubation with rhSP-D. In addition, the
uptake of apoptotic eosinophils by macrophage cell line J774A.1
is signiﬁcantly enhanced by rhSP-D. These two processes may
account for reduction in peripheral and pulmonary eosinophilia
in themousemodels following therapeutic treatmentwith rhSP-D.
CLEARANCE OF APOPTOTIC CELLS BY SP-A AND SP-D
Apoptosis (programmed cell death) and the non-inﬂammatory
removal of dying cells are the important features in embryonic
normal development,maintenance of tissue homeostasis, and res-
olution of inﬂammation (Wyllie et al., 1980; Haslett et al., 1994).
Ineffective clearance of apoptotic cells can lead to the accumula-
tion of late apoptotic cells or secondary necrotic cells in the lungs
(Vandivier et al., 2002; Bianchi et al., 2008; Vandivier et al., 2002;
Litvack and Palaniyar, 2010). An inﬂammatory immune response
may occur to reduce the accumulation of these dying cells (Clark
and Reid, 2002; Palaniyar et al., 2005). SP-A and SP-D have been
shown to enhance apoptotic cell ingestion by resident murine and
human AMs in vitro (Vandivier et al., 2002). SP-D is a potent
modulator of apoptotic cell clearance in a naïve lung when com-
pared to SP-A. SP-A and SP-D bind to apoptotic cells and enhance
apoptotic cell uptake by phagocytes through a mechanism depen-
dent on calreticulin and CD91, similar to that of C1q, suggesting
that the entire collectin family of innate immune proteins (includ-
ing C1q) works through a common receptor complex to enhance
removal of apoptotic cells, and that collectins are integral, organ-
speciﬁc components of the clearance machinery (Vandivier et al.,
2002). In resting, non-inﬂamed lung, lung collectins suppress AM
phagocytic function through interacting with SIRPα and enhance
apoptotic cell removal by opsonizing apoptotic cells and helping
their removal through CD91 (Gardai et al., 2003; Janssen et al.,
2008).
EXTRAPULMONARY EXISTENCE AND FUNCTIONS OF SP-A
AND SP-D
Several immunolocalization studies provide evidence of the
expression of the SP-A and SP-D at extrapulmonary sites. A sig-
niﬁcant level of SP-D has been detected immunohistochemically
in human trachea, brain, testis, salivary gland, heart, prostate,
kidneys, small intestine, pancreas, and placenta. Lower levels of
expression have also been detected in spleen, adrenal gland, uterus,
and mammary glands (Fisher and Mason, 1995; Madsen et al.,
2000; Herias et al., 2007). SP-D immunoreactivity has also been
detected in epithelial cells of large and small ducts of the parotid
gland, sweat and lacrimal glands, epithelial cells of gall bladder and
intra-hepatic bile ducts, exocrine pancreatic ducts, epidermal cells,
esophagus and small intestine, and in the urinary tract, including
the collecting ducts of the kidney (Madsen et al., 2000; Brauer
et al., 2007).
SP-A, on the other hand, is found to be at low levels in the
human and rat small and large intestines (Lin et al., 2001),mesen-
tery, and colon (Rubio et al., 1995; Chailley-Heu et al., 1997;
Madsen et al., 2003). SP-A is found in human prostate, thymus,
amniotic ﬂuid and epithelium, and salivary glands in very low
quantities (Madsen et al., 2003). SP-A has also been detected in the
entire human lacrimal apparatus including lacrimal gland, naso-
lacrimal ducts, conjunctiva, cornea, and human tear ﬂuid (Brauer
et al., 2007). Both SP-A and SP-D have been immunohistochem-
ically localized in the fetal membranes (amniotic epithelium and
chorionic membrane) and the choriodecidual layer of the late
pregnant uterus (Miyamura et al., 1994). SP-A and SP-D, along
with SP-B and SP-C, can be immunohistochemically localized on
the human skin as well as human skin-derived cell lines (Mo et al.,
2007).
The presence of SP-A and/or SP-D in the extrapulmonary envi-
ronment, especially in organs and tissues, which are most exposed
to pathogens, supports their roles as important proteins of the
innate immune system even outside the lungs. The gastrointestinal
tract was the ﬁrst site to be examined for extrapulmonary pres-
ence of the surfactant proteins (Fisher and Mason, 1995; Rubio
et al., 1995). Following immunolocalization, SP-A was found to
be expressed in areas distal to the stomach such as a ﬁne lining
of the luminal surface of villi and on some jejunal cells (Rubio
et al., 1995). On the other hand, SP-D is localized mainly to the
stomach and some parts of the large and small intestine (Fisher
and Mason, 1995; Madsen et al., 2000). The presence of SP-D in
stomach is interesting as it is an organ that is potentially in direct
contact with pathogens. SP-D as a major opsonin is likely to facil-
itate phagocytosis by macrophages of pathogens introduced via
the stomach. In the case of SP-A, it has been known to be involved
in surfactant homeostasis in the lung (Kuroki and Akino, 1991;
Weaver and Whitsett, 1991). The hydrophobic gut lining bears
a strong resemblance to the lung surfactant with phosphotidyl-
choline being the major phospholipid (Lichtenberger et al., 1983).
Hence, SP-A might be involved in the maintenance of the gut
surfactant function.
Consistent with the observation that SP-A and SP-D are mostly
found in tissues susceptible to infection, recent studies have
reported their expression in human paranasal sinus mucosa, as
conﬁrmed by immunolocalization (Woodworth et al., 2006). SP-A
and SP-D are also found in Eustachian tube epithelium (Paananen
et al., 2001). Thus, the potential roles of SP-A and SP-D in mucosal
immunity are likely to be an emerging area of research.
ASSOCIATION OF SP-A AND SP-D IN HUMAN HEALTH AND
DISEASES
A ﬁne-tuned activity of SP-A and SP-D is vital for ﬁrst line host
defense and immune regulation within pulmonary and extrapul-
monary sites. Varying serum levels of SP-A and SP-D have been
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associatedwith a range of diseases including idiopathic pulmonary
ﬁbrosis, sarcoidosis, pulmonary alveolar proteinosis, hypersen-
sitivity pneumonitis, acute lung injury (ALI)/acute respiratory
distress syndrome (ARDS), chronic obstructive pulmonary dis-
ease (COPD), interstitial lung disease (ILD), rheumatoid arthritis
(RA), and systemic scleroderma (Table 3).
Themeannormal serumconcentrationof SP-D ranges between
48.7 and 109 ng/ml (Kuroki et al., 1998) and mean BAL concen-
tration can be 880 ng/ml (Kuroki et al., 1998). The physiological
levels of SP-A in serum is 25 ng/ml (Greene et al., 1999). The phys-
iological levels of these proteins undergo changes when challenged
by external stimuli such as allergens during asthma. Measurement
of the altered expression of these immunomodulatory proteins in
serum during health as well as disease has emerged as important
biomarkers for a range of pathological conditions.
SP-A AND SP-D IN PULMONARY DISORDERS
In lung diseases such as pulmonary ﬁbrosis and idiopathic inter-
stitial pneumonia, the serum levels of the surfactant proteins
(especially SP-D) are inversely related to their respective levels
in the BAL. The widely accepted view is that the underlying dis-
ease mechanism increases the alveolar-capillary permeability and
also affects the basement membrane. These changes lead to the
leakage of the surfactant proteins into the blood vessels and, hence
increase in the overall serum level measurement. For example, in
idiopathic interstitial pneumonia, the basementmembranes of the
alveoli and vessels are injured (Kawanami et al., 1982; Wells et al.,
1993). This, in turn, facilitates the leaking of SP-A from the alveolar
space into the blood vessels (Kuroki et al., 1993). This ﬁnding sup-
ports previous studies in guinea pigs, where exposure to cigarette
smoke increases the alveolar permeability (Simani et al., 1974).
Thus, along with being markers of an underlying lung disease and
its progression, themeasurement of surfactant proteins also acts as
a good marker for alveolar integrity. An exception to the hypothe-
sis is asthma and allergen-induced airway inﬂammation. In these
cases, levels of SP-A and SP-D increase in serum (Koopmans et al.,
2004) as well as BALF (Erpenbeck et al., 2006).
Other conditions linking the levels of the SP-A and SP-D with
pathology are smoking and radiotherapeutic pneumonitis. Serum
levels of the surfactant proteins are seen to be upregulated in smok-
ers when compared to non-smokers (Nomori et al., 1998; Mazur
et al., 2011). Consistent with notion of the high serum levels and
the alveolar-vascular translocation, the BAL levels of SP-D was the
lowest in smokers (12–19μg/ml) when compared to the normal
levels of BAL SP-D (51μg/ml). The decrease in BAL SP-Dmight be
contributing to the host defense imbalance within the lungs, thus
explaining the increase in the incidence of infections in smokers
(More et al., 2010). An increase in serum SP-D and decrease of
BAL SP-D levels not dependent on the occurrence of COPD in
the same individual. In addition to the elevated levels of SP-D,
smoking has also been recently reported to affect the multimeric
structure of the SP-D molecule, forming lower molecular weight
SP-D molecules (Winkler et al., 2011).
In cystic ﬁbrosis (CF), the BAL levels of SP-A and SP-D vary
according to the organ involved and severity of infection. For
example, SP-A and SP-D gene expression has been reported to be
increased in the sino-mucosal tissue in CF patients (Skinner et al.,
2007; Woodworth et al., 2007b). However, during bacterial infec-
tions, especially Pseudomonas aeruginosa, the SP-A and SP-D levels
in the BALF decrease dramatically (Noah et al., 2003). The possi-
ble reason for this decrease might be due to impaired production
of SP-A and SP-D by the respiratory epithelial cells or increased
consumption of SP-A and SP-D due to a demand for increased
phagocytosis of the pathogen involved. Proteolytic degradation of
SP-D by P. aeruginosa elastase and protease IV has been previously
reported, which can lead to hampering of immune functions of
SP-D in the lungs (Alcorn and Wright, 2004a; Malloy et al., 2005).
The level of SP-A and SP-D in serum are likely to be good
biomarkers for the clinical outcomes of certain disorders. For
instance, a decline in the systemic SP-D in COPD has linked with
a better clinical outcome (Sin et al., 2008). ALI and ARDS also
exhibit similar association of serum level of SP-D and mortal-
ity (Eisner et al., 2003). Post-mortem subjects in a study showed
extremely high levels of circulating SP-D when compared to
early-stage ALI/ARDS patients (Eisner et al., 2003).
Inﬂammation of the lungs as an adverse affect of radiation
therapy is termed as radiation pneumonitis. This occurs in 5–
15% of patients undergoing radiation therapy as a treatment of
cancers affecting lungs, breasts, lymphomas, and other cancers.
An increased production of SP-A and SP-D that is correlated to
the intensity of radiation administered has been noticed in lungs
afﬂicted by radiation pneumonitis (Sasaki et al., 2001). About 50–
60Gy of radiation led to 68–74% increase of SP-D levels when
compared to SP-A (21–26%). Thus monitoring of the SP-A and
SP-D levels can potentially be good biomarkers to ascertain side
effects of radiation.
SP-A AND SP-D AND EXTRAPULMONARY DISEASES
SP-A and SP-D found at extrapulmonary sites also exhibit a vary-
ing pattern of expression in response to stimulus. Chronic rhinosi-
nusitis involves inﬂammation of the sinonasal cavity, which can be
triggered by infection, allergy, or other autoimmune conditions.
During episodes of chronic rhinosinusitis, the levels of both SP-
A and SP-D have been reported to be upregulated. For example,
chronic rhino sinusitis due to A. fumigatus exhibited upregulated
levels of SP-D when compared to normal sinonasal tissue (Ooi
et al., 2007). In two separate studies, increased levels of SP-A were
observed during chronic rhinosinusitis as well as allergic rhinitis
(Lee et al., 2006; Wootten et al., 2006).
Rheumatoid arthritis is a chronic inﬂammatory systemic dis-
order that affects a range of tissues and organs, but predominantly
affects the synovial joints. SP-A and SP-D have been detected in
the synovial ﬂuid as part of the lubricating surfactant (Kankavi,
2006). Consistentwith the established surfactant-related functions
of SP-A and SP-D in the lungs, it has been speculated that SP-A
would also facilitate the adsorption of surface-active phospholipid
to the articular surface,whereas and SP-Dmight regulate the phos-
pholipid homeostasis within the joint (Kankavi, 2006). Lamellar
bodies are specialized intracellular organelles of epithelial cells
that are responsible for the packaging and secretion of surfactant
(Dobbie et al., 1995). These lamellar bodies found in synovio-
cytes in joints of patients afﬂicted with RA have been associated
with expression of SP-A (Dobbie, 1996). The lamellar bodies are
known to secrete the endocytosed SP-A. Thus, a 6.1 and 3.5 fold
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increased levels of SP-D and SP-A, respectively, have been reported
inRA synovial ﬂuid (Kankavi,2006).Considerable antigenic cross-
reactivity was observed between SP-A and a mycobacterial heat
shock protein (hsp) 65 (Dobbie et al., 1994). The possibility of
SP-A being a potential autoantigen in RA led to the identiﬁcation
of autoantibodies directed against SP-A within the synovial ﬂuid
(Trinder et al., 2000). On the other hand, recent studies report
the decreased levels of circulating SP-D in RA patients that is
inversely associatedwith disease activity (Hoegh et al., 2008;Chris-
tensen et al., 2010). Decreased levels of SP-D in RA could be due
to the increased clearance of SP-D from the serum by deposi-
tion in the inﬂamed joint or by complex formation with cellular
waste. SP-D as a scavenger molecule enhancing the clearance of
DNA and apoptotic cells via macrophages is likely to reduce the
anti-double-stranded DNA autoantibody production (Palaniyar
et al., 2005). This mechanism is supported by the inverse associa-
tion between SP-D and disease activity measurements and gradual
increase of SP-D levels following treatment. SP-D is accumulated
within the synovial ﬂuid through diffusion into the joint cavity
from the circulation (Kushner and Somerville, 1971; Pejovic et al.,
1995). Interestingly, trimeric forms (130 kDa subunit of SP-D) of
SP-D are abundant in the synovial ﬂuid. Although the functions
of trimeric SP-D are not well documented, it has been demon-
strated to exhibit both pro-inﬂammatory (via calreticulin-CD91)
and anti-inﬂammatory (via SIRPα) functions (Gardai et al., 2003;
Guo et al., 2008). Furthermore recent studies on the disruption of
multimeric SP-D during inﬂammation has shown that this degra-
dation of the multimer into nitrosylated trimeric SP-D exhibits
a pro-inﬂammatory response (Guo et al., 2008). This response is
brought about by the CD91/calreticulin receptor interaction and
consequent p38 MAPK pathway (Gardai et al., 2003; Guo et al.,
2008). Consistent with these ﬁndings, increased inﬂammatory
response is associated with an increase in p38 phosphorylation, an
important determinant of synovitis severity (Schett et al., 2008).
Thus, low levels of SP-D in serum and increased expression of SP-
D in the synovial ﬂuid may contribute to the persistent low-grade
subclinical joint inﬂammation seen in RA patients (Brown et al.,
2006). This can also be a good biomarker of inﬂammation and
disease activity in the RA patients.
SP-D synthesis has been demonstrated to be localized to vas-
cular endothelial cells in both mice and human (Madsen et al.,
2000; Sorensen et al., 2006). The study was carried out in SP-
D−/− and control mice fed on an atherogenic diet. Interestingly,
the SP-D−/− mice was protected against the development of ath-
erosclerotic lesions in the aortic root with very small foamy cell
lesions when compared to the mature cholesterol-laden collage-
nous atherosclerotic plaques in the control mice. Nevertheless,
there was a presence of foamy macrophages within the lung due
to lipid engorgement, a typical feature due to SP-D deﬁciency.
When treated with rhSP-D fragment, the anti-inﬂammatory Th2
response in the blood of the SP-D−/− mice shifted to a Th1
response with the upregulation of the pro-inﬂammatory cytokine
TNFα. Also observed was the reduction of plasma lipid concen-
trations including HDL and LDL. Thus the Th2→Th1 shift along
with increased susceptibility to development of atherosclerosis
suggests the pro-atherogenic potential of SP-D (Sorensen et al.,
2006).
SP-D has also been recently reported to be involved in skin dis-
eases such as psoriasis and atopic dermatitis (Hohwy et al., 2006).
When immunohistochemically stained,affected skinbiopsies from
psoriasis and atopic dermatitis patients showed no difference in
SP-D immunoreactivity to control healthy skin biopsies on the
basal keratinocyte layer level (Hohwy et al., 2006). However, in
the stratum spinosum, where keratinization is initialized, SP-D
showed higher intensity of immunostaining. Interestingly, the
serum level of SP-D was not altered in either condition suggesting
that unlike ILDs inwhich there is a spill-over due to increased alve-
olar permeability, there was no leakage of SP-D from the psoriatic
lesions (Hohwy et al., 2006). The same study also reported that
production of SP-D transcripts was not upregulated, and hence,
the increase in inﬁltrating inﬂammatory cells might be the source
of SP-D in the lesions. This study is supported by the ﬁnding of yet
another study that reports the strong surfactant protein (SP-A, B,
C, and D) expression in the lesions of patients affected with psori-
asis, atopic dermatitis, lichen planus, and Behcet’s disease (Akman
et al., 2008). Thus, further studies are required to elucidate the
exact role and regulation of SP-D in inﬂammatory skin diseases.
SP-A AND SP-D IN REPRODUCTIVE TISSUES
The ubiquitous roles of SP-A and SP-D are extended to the human
reproductive system. Alongside being involved in the respiratory
function of the newborn lung during the transition from the
intrauterine aqueous environment to extrauterine oxygen, the sur-
factant proteins are also involved in the process of parturition and
innate immune mechanisms during pregnancy.
The localization of SP-A and SP-D in the female reproductive
tract suggests the role of these proteins in the process of reproduc-
tion. SP-D has been localized in non-pregnant uterus, ovaries, and
oviduct of humans (Oberley et al., 2004). SP-D protein andmRNA
has been detected in the villous and extra villous trophoblast of the
human placenta (Oberley et al., 2004). SP-D mRNA and protein
have been detected in the vagina, uterus, ovary, cervix, and oviduct
in mouse (Akiyama et al., 2002). Both SP-A and SP-D have been
reported to be present in the genital tract of the mare (Kankavi,
2007).
SP-D mRNA in mouse uterus was reported to be hormonally
regulated, with peak levels present at estrus and the lowest levels
at diesterus (Oberley et al., 2007). Human SP-A has been localized
in both pre- and post-menopausal vaginal stratiﬁed squamous
epithelium as well as in vaginal lavage ﬂuid (MacNeill et al., 2004).
Both SP-A and SP-D can be detected in human amniotic ﬂuid as
early as 26 weeks of gestation. However, by 40 weeks of gestation,
the level of SP-A rises dramatically from 3 to 24μg/ml with a less
pronounced rise of SP-D levels. Thus, the 1:1 ratio of SP-A and
SP-D during 26–34 weeks of gestation rises to a striking 6:1 ratio
by end of term (Miyamura et al., 1994).
ROLE OF SP-A AND SP-D IN MAINTENANCE OF PREGNANCY
The immunoregulatory function of SP-A and SP-D are also seen
in the control of cytokine production within the uterine environ-
ment. During human labor, the intrauterine tissue macrophages,
especially of the decidua, releases excess of prostaglandin F2α
(PGF2α; Norwitz et al., 1992a). Along with the release of PGF2α,
there is a concomitant release of other macrophage-associated
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products such as pro-inﬂammatory cytokine TNF-α (Norwitz
et al., 1992b). Inhibition of TNF-α production by SP-A in lung
macrophages can hinder the premature activation of the PG
cascade, and hence, when this inhibition of pro-inﬂammatory
cytokines takes place during pregnancy, it leads to regulation
of the onset of labor (Alcorn and Wright, 2004b). In support
of this observation, the down regulation of pro-inﬂammatory
cytokines and chemokines (IL1β, CXCL2, CXCL5) was observed
when human amnion explants were incubated with SP-A (Lee
et al., 2010). SP-A and SP-D are also involved in clearance of apop-
totic cells and necrotic cells (Schagat et al., 2001; Jakel et al., 2010)
and this ability to clear dead cells from the uterine tissues can
decrease the chances of inﬂammation due to the presence of dead
cells in the uterine environment (Vandivier et al., 2002).
ROLE OF SP-A AND SP-D IN PARTURITION
Control of parturition depends on genetic, hormonal, mechanical
and/or environmental factors. Research into the control of partu-
rition is of utmost importance as spontaneous pre-term delivery,
i.e., delivery before 37 weeks of gestation, is the major cause of
neonatal mortality. Signals for parturition might arise from either
the maternal side or the fetal side or both (Challis et al., 2005). The
process of parturition is associated with an increase in the release
of PGs into the uterine environment (Keirse, 1978; Gibb, 1998).
The precursor for PG synthesis is arachidonic acid/arachidonate
which involves cleaving of the arachidonate from the phospholipid
by a phospholipase, which in human amnion is, amniocyte diacyl
phosphatidylethanolamine by phospholipase A2 and phospho-
tidylinositol by phospholipase C and diacylglycerol lipase (Okita
et al., 1982). During the development of the fetal lung, the surfac-
tant is synthesized and released to the surrounding amniotic ﬂuid.
The process of parturition and fetal lung maturation has been
closely associated since survival of the neonate is closely linked
with development of surfactant within in the fetal lung (Pryhuber
et al.,1991).Respiratory failure due to abnormal lungdevelopment
is responsible for majority of neonatal death observed in pre-term
babies. The link between the fetal lung surfactant protein levels and
the initiation of pre-term labor is supported by the observation
that the fetal surfactant has also been associated with contributing
arachidonate for PG synthesis by amnion cells (Bernal and Phiza-
ckerley, 2000). In full-term labor, the secretion and accumulation
of fetal surfactant into the amniotic ﬂuid in the third trimester of
pregnancy might lead to the gradual increase of PG that induces
normal birth. However, in pre-term labor, retarded lung matura-
tion might be leading to an excessive secretion of surfactant, and
thus of arachidonate, which contributes to early enhancement of
PG production, that in turn, induces labor and leads to pre-term
birth. Recent studies have shown that the surfactant proteins, espe-
cially SP-A, is directly linked to the inductionof parturition inmice
(Condon et al., 2004).
Initiation of labor is associated with an inﬂammatory response
characterized by an increased production of IL-1β and NF-κB
by intrauterine macrophages. Intra-amniotic injection of SP-A in
mice caused pre-term delivery within 6–24 h and intra-amniotic
administration of an SP-A antibody or NF-κB inhibitor delays
labor by 24 h (Condon et al., 2004), thus facing apro-inﬂammatory
action at the end of gestation. SP-A has been reported to induce
direct stimulation of IL-1β and NF-κB expression by decidual
macrophages in the amniotic ﬂuid (Condon et al., 2004). This
increase of pro-inﬂammatory cytokines leads to the PG cascade
which in turn leads to the onset of labor. Thus, SP-A appears to
be a potential initiator of parturition. Yet another study that sup-
ports the pro-parturition effects of SP-A is the potential ability of
SP-A to induce stress ﬁbers by regulating F-actin ﬁlament organi-
zation in cultured humanmyometrial cells (Breuiller-Fouche et al.,
2010). Stress ﬁbers are dynamic structures that aid in maintaining
the endothelial cell integrity during the exertion of tensile stress
on the vessel wall during growth of the uterine body (Sago et al.,
1993). Thus, SP-A may be a vital pro-parturition, immunoregula-
tory molecule during pregnancy where a delicate balance between
stringent host defense and protection of allogenic fetus is required.
However, the levels of SP-A is observed to decrease rapidly in spon-
taneous human parturition at full-term (Chaiworapongsa et al.,
2008). This is in comparison to subjects at full-term but not in
labor. Further studies into the effects caused by the sudden with-
drawal of expression of SP-A in the amniotic ﬂuid can show the
association of surfactant proteins at term and how it modulates
the process of parturition.
SP-A AND SP-D IN FETAL AND NEONATAL ORGANS
Expression of SP-D has been detected in newborn infant umbilical
cord blood and capillary blood. The varied levels in the capillary
blood reﬂected the mode of delivery, with the highest levels being
detected in newborns being delivered through cesarean section
(Dahl et al., 2005). This study showed that the perinatal condi-
tions played an important role in regulation of the levels of SP-D
in the newborn circulation. High levels of SP-D in the cord blood
are likely to be inﬂuenced by mother’s smoking habits (Dahl et al.,
2005). Smoking during pregnancy also decreases the levels of SP-D
in the capillary blood of the newborn (Dahl et al., 2006). Smoking
may lead to decrease in trophoblast proliferation and reduction of
the length of villous capillaries in the placenta leading to abnormal
gas and nutrient exchange (Larsen et al., 2002).
The human fetal lung expresses SP-A and SP-D and the pro-
duction of SP-D has been detected in bronchiolar and terminal
epithelium at 16–21 weeks of gestation by hybridization and
immunohistochemical analysis (Dulkerian et al., 1996; Mori et al.,
2002). Several studies have reported that after the production
of SP-D, it begins to peak gradually during gestation and then
peaks down during later stages of gestation (Dulkerian et al., 1996;
Stahlman et al., 2002). This is evident from the observation that
umbilical cord blood SP-D levels were twice as high in prema-
ture infants when compared to the full-term babies (Dahl et al.,
2006). The same study also reported that neonate with high levels
of SP-D in the umbilical blood and capillary blood later developed
sepsis. This increase has been speculated to be due to a capillary
leak leading the decrease of SP-D in the neonatal lung. This, in
turn, will increase the susceptibility of the newborn to infections
or due to pro-inﬂammatory effects of SP-D such as stimulation of
TNF-α production induced by LPS, as evident in studies on pre-
mature newborn baboons (Awasthi et al., 2001). The higher levels
of SP-D in umbilical cord blood observed in Dahl et al., 2006 has
been speculated to be due to the impairment of alveolar-vascular
integrity during development and that the leakage of proteins into
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circulation might have taken place even before birth. Regulation
of inﬂammation in newborns by SP-D has also been shown in ani-
mal studies. When surfactant mixed with SP-D was administered
to premature newborn lambs under ventilation for resuscitation,
the SP-D was seen to inhibit lung inﬂammation caused by the ven-
tilation with downregulated levels of pro-inﬂammatory cytokines
(Sato et al., 2010).
SP-A, apparently an important player in pregnancy and partu-
rition, is also involved in neonatal immunity. Inmice studies,prog-
eny of SP-A−/− mice bred in bacteria-laden environment showed
a high rate of mortality (P < 0.001) compared to wild-type mice
(P < 0.05; George et al., 2008). Interestingly, the progeny of SP-
A−/− showed signiﬁcant gastrointestinal tract pathology (Bacillus
sp. and Enterococcus sp. Peritonitis) and blood congestion in lung
tissue due to systemic inﬂammation and consequent upregulation
of pro-inﬂammatory cytokines. The GI tract pathology may arise
due to ingestion of bacteria during nursing. However, when the
SP-A−/− pupswere administered SP-Aorally, therewas an increase
in the rate of survival. Thus, SP-A is seen to play a critical role in
immunoprotection of newborn mice (George et al., 2008).
SP-A and SP-D are also involved in dealing with intrauterine
infections. Infection within the sterile intrauterine environment
can lead to the initiation of inﬂammation which might lead to
pre-term labor (Kim et al., 2009). This would include an exagger-
ated pro-inﬂammatory cytokine response that in turn would lead
to release of PGs that can induce parturition by pre-term cervical
softening, contractions and rupture of the protective fetal mem-
branes. The localization of the SP-A and SP-D in fetal membranes
and uterine tissue (Miyamura et al., 1994) supports their role
in active host defense mechanisms, including during intrauterine
infections.
Chorioamnionitis is the inﬂammation of the fetal membranes
due to a bacterial infection. Bacterial infection in this context
would mean an inﬂux of PGs, cytokines, and other mediators
of inﬂammation. Pregnancy demonstrates a strong Th2 charac-
ter at the feto-maternal interface in which there is a predomi-
nance of immunosuppressive activity, including elevated levels of
anti-inﬂammatory mediators such as IL-10, and lowered levels
of pro-inﬂammatory cytokines, such as IL-1β and TNF-α. How-
ever, the presence of bacterial products such as LPS can switch
on pro-inﬂammatory cytokine production and lead to unwanted
expulsion of the fetus from the uterus. Chorioamnionitis is com-
monly developed at 26–32 weeks of gestation when SP-A (Wang
et al., 1996) and SP-D levels are low (Lahra and Jeffery, 2004). The
association of the low levels of SP-A and SP-D and the consequent
susceptibility of the fetalmembranes tobacterial challengedemon-
strate the importance of SP-A and SP-D in immunoregulation and
primary host defense against pathogens during pregnancy.
CONCLUSIONS
Studies involving gene knockout mice, murine models of lung
hypersensitivity and infection, and functional characterization
of cell surface receptors have revealed the diverse roles of SP-
A and SP-D in the control of lung infection and inﬂamma-
tion. Studies that demonstrate how a range of immune cells,
cytokines/chemokines, and surface receptors are modulated by
SP-A and SP-D in response to pathogens and allergens in a given
microenvironment are crucial in understanding how these pro-
teins link innate and adaptive immunity. The therapeutic effects
of rhSP-D in allergic and invasive aspergillosis in murine mod-
els are worth investigating as a follow-up clinical trial as an
adjunct therapy especially in IPA. Clearly, SP-A and SP-D levels
and SNPs in various forms of respiratory diseases are likely to
ﬁnd their translational applications. A recently proposed model
based on studies with the calreticulin-CD91 complex as a recep-
tor for SP-A and SP-D has suggested an anti-inﬂammatory role
for SP-A and SP-D in naïve lungs which would help minimize the
potential damage that continual low level exposure to pathogens,
allergens and apoptosis can cause. However, when the lungs are
overwhelmed with exogenous insults, SP-A and SP-D can assume
pro-inﬂammatory roles in order to complement pulmonary innate
and adaptive immunity (Gardai et al., 2003). However, the in vitro,
in vivo, and ex vivo effects of rhSP-D, which is composed of
homotrimeric neck and CRD region, appear to suggest the exis-
tence of additional, crucial SP-D receptor(s) that is speciﬁc to
the lectin domain. Identifying extrapulmonary functions of SP-
A and SP-D at mucosal surfaces remain an attractive area of
research. Thus, how SP-A and SP-D are involved in the main-
tenance of pregnancy and subsequent parturition need further
investigation.
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